secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2026-10-29T20:12:11+00:00
Accession:  0001790340-26-000095
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Immuneering Q3 2026 net loss $24.2M; MAPKeeper 301 enrollment ahead of schedule, runway to 4Q 2028
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders $24.2M, or $0.37/share, vs $15.0M ($0.38/share) in Q3 2025; R&D $20.7M vs $10.9M on higher clinical and personnel costs.
- Cash, cash equivalents and marketable securities $166.1M at Sept 30, 2026, down from $217.0M at Dec 31, 2025; runway now funded into 4Q 2028.
- Phase 2 1L pancreatic cancer atebimetinib + mGnP arm (N=55) follow-up extended because patients are living longer than projected; topline update now 1H 2027.
- Phase 3 MAPKeeper 301 enrollment ahead of schedule; target expanded from 510 to ~570 patients, with potential to accelerate current mid-2028 topline guidance.
- CEO Zeskind cited 17.3 months median overall survival reported at ASCO; first lung cancer patient in atebimetinib + cemiplimab Phase 2 dosed in 4Q 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/0001790340-26-000095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029.htm
  HTML page:      https://secwatch.observer/filing/0001790340-26-000095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer